Biotechs Buffeted by Macro News But Should Continue to Outperform…Update-1
Update-1 March 10... Broad Rally Continues Through The Week QQQ Up 4.3% IBB up 4.3% XBI up 4.8% Gene Editing Stocks Surge Biotech stocks soared along with the market as fear about interest rates, tariffs and global politics subsided helped considerably by economic sentiment and jobs. Moreover...
Sluggish Tape And Possibly An End to Celgene Woes?…Update
Update after close 2/28/18 Tape deteriorates at last hour of trading, a familiar pattern: IBB down 1.83%, QQQ down 0.64%, XBI down 1.88% for day. Biotechs still up YTD with XBI;FBT down 2.35% but still up 8.28% YTD. Celgene, Inc (CELG) sell-off continues down 9% to $87.12 on 27.87M share...
Large Cap Biopharmaceuticals Performance Update 2018: Part 2
Large Cap Biopharmaceuticals: Winners and Losers, Takeaways Here is a brief analysis from data below. Data Sources : Google Finance and FinViz.com. Our Top Picks continue to do well: Abbvie (ABBV), Bristol-Myers Squibb (BMY) and Gilead Sciences (GILD). Laggards in our focus group are Biogen...
Rayno BioBeat 2018 #2: Biotech Deal Sparks Rally…Update-1
Update-1 ...2/17/18 Good Week for Biotech: FBT up 6.29%, IBB up 4.44%, XBI up 6.26% Biotech stocks continued their strong recovery from the big sell-off in the prior week but about 3% under 2018 highs. Biotech ETFs tracked the QQQ up 5.68% for the week but biotech stocks are leaders YTD beating...
Large Cap Biopharma Performance Update 2018-Part 1
Large Cap Biopharmaceuticals Performance Part 1- After Correction Technicals: we are holding the December 2017 bottom but 2018 gains on some indices have been wiped out with peak values on Jan. 26. The FBT was the top performing ETF in 2018 YTD. Many of our picks have outperformed the market....